• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Breaking News: Terran Biosciences Sues Compass Pathways for Stealing Trade Secrets

Microdose NewsDesk by Microdose NewsDesk
August 9, 2022
in Industry
Reading Time: 1 min read
A A
Breaking News: Terran Biosciences Sues Compass Pathways for Stealing Trade Secrets

Big industry news as Terran Bioscience sues Compass Pathways for allegedly stealing trade secrets.

According to the court filings and with a shout-out to Psychedelic Alpha for breaking the news, Compass allegedly entered into negations and signed an NDA with a researcher regarding psilocybin development, before ending the talks and “milking” him for this confidential research.

Is there any substance to these allegations? Unknown, we’ll reach out to the parties for comment. In the meantime see Psychedelic Alpha’s Twitter thread below for more details on the news.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Terran Biosciences alleges that Compass Pathways stole trade secrets from UMB researcher, then filed patents on them.

"Compass milked Thompson for all the information it could about his confidential research."

🧵 Quick thread… https://t.co/4GaD3wHCxU

— Psychedelic Alpha (@Psyched_Alpha) August 9, 2022

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

 

https://twitter.com/Psyched_Alpha/status/1557013366270578688

Buy Lasix Reliable
[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: COMPASS Pathways
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Optimi Health Launches Psilocybin Product w Patient Advocate Thomas Hartle

Optimi Health Launches Psilocybin Product w Patient Advocate Thomas Hartle

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.